SCM
XENE icon

Stonepine Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Stonepine Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-98,860
Closed -$1M – 30
2019
Q1 		$1M Buy
+98,860
New +$838K 0.58% 28
2018
Q4 		– Sell
-100,000
Closed -$1.32M – 29
2018
Q3 		$1.32M Buy
+100,000
New +$1.16M 0.77% 25

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Stonepine Capital Management's XENE Position: Q2 2019 in Review

Stonepine Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q2 2019, closing a stake of 98,860 shares — an estimated $1M sold.

Stonepine Capital Management first reported a position in XENE in Q3 2018 and held it in 2 quarters. The position peaked at $1.32M in Q3 2018. 60 funds tracked by Wall St. Rank hold XENE as of Q2 2019.

  • Stonepine Capital Management reported no remaining Xenon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Stonepine Capital Management sold 98,860 Xenon Pharmaceuticals shares in Q2 2019, an estimated $1M.
  • Stonepine Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Stonepine Capital Management's Xenon Pharmaceuticals position peaked at $1.32M in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2019.

Based on Stonepine Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.